--- title: "U.S. stock night market volatility: XORTX Therapeutics fell 7.59% in after-hours trading, market volatility intensified, and capital flow has drawn attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/284168109.md" description: "XORTX Therapeutics fell 7.59% in after-hours trading; Novo Nordisk fell 0.17% in after-hours trading, with a transaction volume of USD 7.47 million; Organon rose 15.99% in after-hours trading, with a transaction volume of USD 5.57 million; Eli Lilly rose 0.21% in after-hours trading, with a transaction volume of USD 4.32 million" datetime: "2026-04-27T07:22:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284168109.md) - [en](https://longbridge.com/en/news/284168109.md) - [zh-HK](https://longbridge.com/zh-HK/news/284168109.md) --- # U.S. stock night market volatility: XORTX Therapeutics fell 7.59% in after-hours trading, market volatility intensified, and capital flow has drawn attention **U.S. Stock Night Market Movements** XORTX Therapeutics fell 7.59% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks Ranked High in Industry Trading Volume** Novo Nordisk fell 0.17% in the night market. Based on recent news, 1. On April 25, Eli Lilly's newly launched oral weight loss drug Foundayo had initial prescription volumes far below Novo Nordisk's oral version Wegovy, raising market doubts about its ability to catch up with Novo Nordisk in the oral weight loss drug sector. After the news was released, Eli Lilly's stock price dropped 8% in pre-market trading, while Novo Nordisk's stock price rose 4%. 2. On April 24, Novo Nordisk announced that its oral semaglutide significantly improved blood sugar management in children and adolescents with type 2 diabetes in the PIONEER TEENS trial, planning to apply for expanded label regulatory approval in the second half of this year. After the news was released, Novo Nordisk's stock price rose 3.66%. 3. On April 23, Novo Nordisk's oral semaglutide showed superior efficacy compared to placebo in a 52-week study, expected to be the first oral treatment to demonstrate superior efficacy in this age group. Novo Nordisk's stock price rose 0.05% in pre-market trading. The weight loss drug market is highly competitive, and Novo Nordisk maintains its lead. Organon rose 15.99% in the night market. Based on recent key news: 1. On April 27, Sun Pharmaceutical announced an all-cash acquisition of Organon, valuing the company at $11.75 billion. This news drove Organon's stock price up, with significantly increased trading volume. Source: Zhitong Finance 2. On April 27, the acquisition agreement by Sun Pharmaceutical has been approved by the boards of both companies and is expected to be completed in early 2027. This transaction will expand Sun Pharmaceutical's capabilities in women's health and biosimilars, further boosting market confidence. Source: Zhitong Finance 3. On April 25, Organon's stock price rose 25.47% after the acquisition announcement, continuing its upward trend since the beginning of the year. This news has attracted significant market attention to Organon, with active trading. Source: Investing.com The pharmaceutical industry is experiencing frequent M&A activities, leading to increased market volatility. Eli Lilly rose 0.21% in the night market. Based on recent news, 1. On April 24, Eli Lilly's newly launched oral weight loss drug Foundayo had initial prescription volumes far below competitor Novo Nordisk, raising market doubts about its ability to catch up with Novo Nordisk in the oral weight loss drug sector. After the news was released, Eli Lilly's stock price dropped 8% in pre-market trading, while Novo Nordisk's stock price rose 4%. 2. On April 25, Caixin reported that Eli Lilly's new weight loss pill Foundayo's initial performance was below expectations, with the latest prescription data showing that the product started slowly, highlighting the challenges it faces in catching up with competitor Novo Nordisk Affected by this news, Eli Lilly's stock price fell by 5% in early trading on the US stock market, and the decline has now narrowed to around 4%; Novo Nordisk is currently up 6%. On April 25, Barclays released a report indicating that AI is impacting the pharmaceutical sector, with Eli Lilly being considered one of the recent winners. Analysts stated that the company may see the first tangible benefits from early investments this year. The competition in the oral weight loss drug market is fierce, with Novo Nordisk maintaining its lead ### Related Stocks - [XRTX.US](https://longbridge.com/en/quote/XRTX.US.md) ## Related News & Research - [Eli Lilly stock: Next stop $2,000?](https://longbridge.com/en/news/286829092.md) - [AM Investment Strategies LLC Sells 1,038 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/286522809.md) - [Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals](https://longbridge.com/en/news/286789989.md) - [Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report](https://longbridge.com/en/news/286951567.md) - [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md)